Close Menu

NEW YORK – EverlyWell has added PerkinElmer to its network of laboratory providers, the companies announced today.

The first tests to be made available through the collaboration will be for Lyme disease and food sensitivity, leveraging Waltham, Massachusetts-based PerkinElmer's expertise. Both tests use dried blood spot testing and were developed by PerkinElmer Genomics. The partners also will work to expand Austin, Texas-based EverlyWell's test menu.

Additional terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.